Three Eras of Bispecific Antibody Manufacturing Innovation

Bispecific antibody (BsAb) manufacturing has evolved through three distinct periods since the first hybrid hybridoma approach was patented in 1995, with each era defined by the dominant technical problem its innovators were trying to solve. The 80+ patent records in this landscape dataset span from 1995 to 2026 across four interrelated technical dimensions: molecular architecture and format engineering for correct heavy-chain pairing; upstream bioproduction including cell culture and perfusion strategies; downstream purification, formulation, and stability optimisation; and novel synthesis chemistries including chemical conjugation and prokaryotic expression.

The foundational period (1995–2010) is represented in this dataset by a single entry: a hybrid hybridoma-derived anti-CD3/anti-EGFR bispecific from Menarini Ricerche Sud S.p.A. (Italy, 1995). That early approach used protein A chromatography followed by cation exchange to separate the desired heterodimer from parental homodimers — illustrating how chain mispairing has been the defining manufacturing challenge from the field’s outset.

The structural engineering and platform buildout period (2010–2020) introduced the core manufacturing methods that underpin most commercial bispecifics today: Genmab’s Fab-arm exchange (FAE) platform (first filed 2010), Regeneron’s common light chain (CLC) strategy (2015), Amgen’s BiTE format scaling, and Chugai Seiyaku’s factor VIII cofactor-mimicking bispecific (2016). Click-chemistry approaches for chemically-locked heterodimers also emerged during this period (Sorrento Therapeutics, 2020).

The scale-up, continuous manufacturing, and Chinese market entry period (2020–2026) is characterised by process intensification — most notably Amgen’s perfusion-based continuous manufacturing filings from 2019 through a 2025 US active patent — alongside a surge of novel compact formats from Chinese biotechs including RemeGen, Betta Pharmaceuticals, WuXi Biologics, Biotheus, Harbour Biomed, Innovent Biologics, and Inmagene, among others.

Fc-Region Engineering: Solving the Chain Mispairing Problem

The largest cluster of patents in this dataset addresses a single fundamental problem: ensuring that when two different heavy chains are expressed in the same host cell, they preferentially pair with each other rather than forming homodimers. Three principal Fc-engineering strategies have emerged as the dominant solutions, each with distinct IP ownership and manufacturing implications.

Fab-Arm Exchange (FAE) — Genmab’s Platform

Genmab A/S developed the foundational Fab-arm exchange method, first filed in 2010 and extended through multiple continuations to 2017. In this approach, two separate IgG4-like half-antibodies are produced independently in separate cell lines, then combined under mild reducing conditions to undergo controlled disulfide-bond isomerisation at the hinge, yielding near-quantitative bispecific product. Because no co-expression of mismatched chains is required, the method sidesteps chain mispairing entirely at the upstream stage — a significant manufacturing advantage that made FAE a foundational production platform, as recognised by WIPO patent databases tracking the method’s international prosecution history.

Knob-into-Hole and Charge-Pair Mutations — Roche, EngMab, and Chinese Biotechs

Knob-into-hole (KiH) engineering — introducing complementary steric mutations into the CH3 domains of two different heavy chains — is used extensively by F. Hoffmann-La Roche, Bristol-Myers Squibb, and multiple Chinese biotechs. A representative example from EngMab SARL (2023) describes K213E/K147E and E123R/Q124K charge-pair substitutions in a BCMA×CD3 format to steer preferential heavy-chain pairing and reduce mispairing side products, directly facilitating downstream purification. Beijing Hanmi Pharmaceutical’s 2020 filing on an anti-PD-L1/anti-CD47 bispecific similarly employs a natural-antibody-like heterodimeric structure using KiH principles.

Common Light Chain (CLC) Strategy — Regeneron

Regeneron Pharmaceuticals’ common light chain strategy — patented in filings from 2015 and 2017 — engineers a single universal light chain that pairs productively with two different heavy chains. This eliminates light-chain mispairing, a distinct bottleneck from heavy-chain mispairing, and enables co-expression of both heavy chains and the shared light chain in a single host cell. The approach underpins Regeneron’s VelocImmune platform and has been adopted as a manufacturing foundation for multiple clinical-stage bispecifics.

Compact and Non-IgG Formats: Simpler Expression, Tunable Valency

A second major cluster departs from full-length IgG architecture to achieve simpler expression, smaller molecular weight, or tunable valency — each property directly relevant to manufacturing yield, purification tractability, and clinical delivery route. Four sub-formats are represented in this dataset.

BiTE (Bispecific T Cell Engager) / Tandem scFv — Amgen

Amgen’s BiTE format — two single-chain variable fragments (scFv) connected by a peptide linker, lacking an Fc domain — was among the earliest non-IgG bispecific formats to reach clinical scale. BiTE molecules are smaller than full IgG bispecifics, simplifying expression in CHO cells but requiring more frequent dosing due to short half-life. More recent Amgen filings extend the BiTE format with Fc domains for half-life extension, as detailed in a 2018 Singapore filing and a 2016 Hungarian filing covering high-molecular-weight target antigens.

VHH-Based (Nanobody) Bispecifics — RemeGen and Boehringer Ingelheim

Single-domain antibody fragments (VHH) derived from camelid antibodies offer high thermal stability, ease of expression, and efficient purification — properties that directly address manufacturing yield and process development timelines. RemeGen Co., Ltd.’s 2025 Israel filing explicitly cites these advantages for a PD-1/VEGF dual-targeting VHH-IgG fusion. Boehringer Ingelheim’s 2013 filing on VHH-based anti-angiogenesis bispecifics established the format’s early precedent, consistent with EPO records on nanobody format patent prosecution in Europe.

Tetravalent Symmetric Formats — Wuhan YZY Biopharma

Wuhan YZY Biopharma’s 2022 EP and 2023 US filings describe novel IgG-like architectures combining F(ab)₂-(Fv)₂-Fc arrangements in homodimeric configurations using identical heavy and light chains. The symmetric design addresses classical manufacturing complexity by eliminating the need for asymmetric chain-pairing engineering — a structurally elegant solution that enables standard monoclonal antibody-like expression and purification processes.

Peptidic and Chemical Conjugation Bispecifics

The Hong Kong Polytechnic University’s 2023 WO filing describes a one-pot chemical synthesis that attaches cyclic tumor-targeting peptides to the surface of conventional monoclonal antibodies via bio-orthogonal click chemistry, producing a hybrid peptide-antibody bispecific without recombinant chain co-expression challenges. Sorrento Therapeutics’ 2020 EP filing on chemically-locked IgG bispecifics similarly uses chemical conjugation to lock heterodimers post-expression. Both approaches represent early-stage but strategically important alternatives to recombinant co-expression platforms.

“Fewer than 8 filings in the dataset address bispecific antibody formulation stability as a primary claim, versus 50+ covering structure or target biology — an imbalance that represents a potential white space for IP capture.”

Continuous Bioprocessing: Amgen’s IP Stronghold

Continuous perfusion-based manufacturing is becoming the industrial standard for bispecific antibody upstream production — and Amgen holds a concentrated IP position across the core patents covering this approach. The dataset contains at least 4–5 Amgen patent families covering perfusion bioreactor control for bispecific products across CA, SG, US, and AU jurisdictions, representing a significant barrier for any organisation seeking to implement continuous manufacturing for BsAbs without a licensing arrangement.

The key innovation across Amgen’s continuous manufacturing portfolio is a two-loop perfusion control strategy: a first control loop regulates medium level in the bioreactor; a second loop regulates viable cell biomass via permittivity or Raman probes, maintaining bioreactor product concentration below a defined threshold. This threshold management is critical for bispecific antibodies specifically, because labile bispecific formats are more prone to product-related impurities — aggregates, fragments, and misassembled species — when product accumulates at high concentrations in the bioreactor environment.

Genentech’s 2023 JP filing on prokaryotic (E. coli) two-chain expression for bispecifics — using controlled growth/production phase temperature and agitation for two-chain assembly — represents an alternative upstream approach that avoids mammalian cell culture entirely. This approach trades the glycosylation capabilities of CHO expression for simpler process control and potentially lower cost of goods, a trade-off that may be acceptable for certain non-glycan-dependent bispecific formats such as BiTEs and VHH fusions. According to FDA guidance on biologics manufacturing, process characterisation for continuous manufacturing requires additional analytical controls compared to batch processes, adding regulatory complexity that Amgen’s IP portfolio appears to address directly.

Application Domains: Oncology, Autoimmunity, Hematology, and Ophthalmology

Bispecific antibody patent activity spans four distinct clinical application domains in this dataset, with oncology — specifically T cell redirection — accounting for the largest cluster. Each domain presents distinct manufacturing requirements driven by the molecule’s mechanism of action and clinical delivery route.

Oncology: T Cell and NK Cell Redirection

T cell engagers (TCEs) using CD3 as the effector arm dominate the oncology cluster, targeting tumour-associated antigens including DLL3 (small cell lung cancer, Amgen 2021), MUC16 (Regeneron 2021), BCMA (EngMab SARL 2023), EGFR, EpCAM, and CD19. NK cell engagers (NKEs) represent an emerging adjacent format, as evidenced by NextPoint Therapeutics’ 2023 CA filing. The manufacturing challenge for T cell engagers is particularly acute: BiTE-format molecules lack Fc domains and require continuous infusion, while Fc-bearing TCEs must balance half-life extension with acceptable cytokine release profiles — a formulation and process challenge as much as a molecular design one.

Oncology: Checkpoint and Angiogenesis Dual Blockade

A second major oncology cluster addresses simultaneous immune checkpoint inhibition and tumour angiogenesis suppression — predominantly combining PD-1/PD-L1 blockade with VEGF or VEGF/Ang2 inhibition. WuXi Biologics (2021 WO), Biotheus Inc. (2023 EP), Eli Lilly/Zymeworks (2019 SG), and F. Hoffmann-La Roche (2018 IN, 2019 AU) all filed in this space. The mechanistic rationale — combining immunotherapy and anti-angiogenics in a single molecule — is well-supported by clinical data tracked by Nature Medicine and related journals, and the manufacturing implication is that full-length IgG formats are preferred to preserve Fc-mediated half-life.

Autoimmune and Inflammatory Disease

Multiple filings address dual cytokine blockade for autoimmune indications. Target pairs in the dataset include IL-17A/F + IL-23 (Bristol-Myers Squibb, 2018 EP), CGRP + IL-23 (Eli Lilly, 2018 IL), TNFα + IL-23 (Inmagene Biopharmaceuticals, 2024 WO), IL-4 + IL-13, and IL-6 + IL-23 — reflecting a strategy of blocking converging inflammatory pathways with a single molecule. Ono Pharmaceutical’s 2020 CA filing on a PD-1/CD19 bispecific for autoimmune B cell depletion represents a distinct immunological mechanism within this cluster.

Hematology and Ophthalmology

Chugai Seiyaku’s factor VIII cofactor-mimicking bispecific (2016 AU, active) — bridging factors IXa and X to replace cofactor function in haemophilia A — represents the rare non-cancer indication where bispecific antibody mechanism of action is inherently structural rather than cell-killing. This molecule, emicizumab, is manufactured as a full-length IgG bispecific using asymmetric Fc engineering. In ophthalmology, Innovent Biologics’ 2025 IL filing on a VEGF/Ang2 formulation for intravitreal administration signals a dedicated formulation cluster for ocular bispecifics, where smaller molecular weight and intravitreal delivery route impose distinct stability and viscosity requirements relative to systemic oncology formats.

Geographic and Assignee Landscape: Chinese Biotechs Accelerate

The geographic distribution of filings in this dataset reflects international patent prosecution strategies rather than market concentration: Israel (IL) is the most frequently cited jurisdiction (~25 entries), followed by Singapore (SG, ~10), Australia (AU, ~8), PCT international (WO, ~8), Europe (EP, ~6), Canada (CA, ~5), and the US (~3). The heavy representation of IL, SG, and AU reflects PCT national phase entry strategies used by both Western and Chinese innovators seeking broad geographic protection.

US jurisdiction is notably underrepresented in the dataset relative to the actual size of the US BsAb patent portfolio, suggesting the dataset is weighted toward PCT/national phase filings outside the US. Among the dominant assignees, Amgen (US/DE) leads in process manufacturing IP, Genmab (DK) leads in production method platforms, and Chinese biotechs dominate the 2022–2025 structural format filings.

The emergence of Chinese biotechs as a new entrant cluster is one of the most strategically significant signals in this dataset. Eight or more Chinese-origin assignees — including RemeGen Co., Ltd.; WuXi Biologics (Ireland/Shanghai); Biotheus Inc.; Betta Pharmaceuticals Co., Ltd.; Wuhan YZY Biopharma Co., Ltd.; Harbour Biomed (Shanghai) Co., Ltd.; Innovent Biologics (Suzhou) Co., Ltd.; Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd.; Excyte Biopharma Ltd.; Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.; and AmpSource BioPharma Shanghai Inc. — filed patents across IL, AU, WO, EP, and US jurisdictions in the 2022–2025 period. Their primary focus areas are VHH fusions, PD-1/VEGF dual blockade, TGF-β/PD-L1, TNF-α/IL-23, and novel structural formats, signalling an acceleration from preclinical to patent prosecution stage with competitive pressure on Western incumbents in Asia-Pacific markets.

Emerging Directions and Strategic White Spaces

The most recent filings (2023–2026) in this dataset signal five directional shifts that collectively define the frontier of bispecific antibody manufacturing technology — and reveal where IP white space remains available for capture.

1. VHH-Fusion Bispecifics for Simplified Expression

RemeGen’s 2025 IL filings use VHH nanobody domains fused to conventional IgG for PD-1/VEGF dual targeting, explicitly citing advantages in thermal stability, purification tractability, and animal model cross-reactivity — properties that directly address manufacturing yield and process development timelines. VHH domains are increasingly preferred by Chinese biotechs for their expression efficiency in standard CHO platforms.

2. Compact Mixed-Architecture Formats (H2L2 + HCAb)

Harbour Biomed’s 2025 EP and AU pending filings describe hybrid architectures combining conventional H2L2 IgG domains with heavy-chain-only antibody (HCAb) VH domains — reducing molecular weight and polypeptide chain count while enabling tunable valency. This approach addresses the classical manufacturing complexity of asymmetric bispecifics by reducing the total number of distinct polypeptide chains that must be correctly assembled.

3. Protease-Activatable Bispecifics

A 2024 WO filing from Zhejiang Shimai Pharmaceutical introduces protease-cleavable linkers into recombinant bispecific designs, enabling tumour-microenvironment-selective activation. This approach adds a precision selectivity layer to manufacturing design that requires controlled linker chemistry and stability testing — creating a new formulation and analytical sub-challenge distinct from the structural mispairing problem.

4. Ophthalmology-Optimised Formulations

Innovent Biologics’ 2025 IL filings explicitly address smaller molecular weight bispecifics for intravitreal administration, targeting VEGF/Ang2 for ocular neovascular disease. The manufacturing challenge for ocular bispecifics is distinct from systemic oncology formats: viscosity, osmolality, and particle size must be controlled within narrow ranges for intravitreal injection, and the smaller molecular weight of some formats (e.g., Fab-based or VHH-based bispecifics) simplifies this relative to full IgG molecules.

5. Formulation Science as an IP White Space

Among all retrieved results, fewer than 8 filings address formulation stability as a primary claim, versus 50+ covering structure or target biology. This imbalance represents a potential white space for IP capture, particularly for novel stabilisation approaches — pH control, co-solute systems, lyophilisation conditions — that address the known physicochemical liabilities of bispecifics relative to monoclonal antibodies. Amgen (BiTE formulation, 2019 SG), F. Hoffmann-La Roche (2020 IL), and Regeneron (anti-CD20×anti-CD3, 2022 IL) have begun filing in this space, but it remains significantly underserved relative to its clinical importance. This is consistent with broader trends in biologics formulation science tracked by NIH‘s National Institute of Biomedical Imaging and Bioengineering, which identifies formulation as a critical gap in complex biologics development.

R&D teams entering the bispecific antibody manufacturing space in 2026 face a landscape where Fc-engineering IP positions are well-established among Western players, continuous manufacturing IP is tightly concentrated in Amgen, and Chinese biotechs are filing internationally at scale across novel structural formats. The clearest opportunities for new IP capture lie in formulation science, novel synthesis modalities (chemical conjugation, prokaryotic expression, protease-activatable linkers), and ophthalmology-specific delivery engineering — areas where the current patent density is low relative to the clinical and commercial opportunity. Organisations can use platforms such as PatSnap’s IP management tools to systematically map white spaces and monitor competitor filing activity in real time.